Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Creo Medical ( (GB:CREO) ) is now available.
Creo Medical Group PLC reported strong financial results for FY24, with a significant 74% increase in Core Technology revenues driven by the commercial rollout of Speedboat UltraSlim. The company’s strategic moves, including the sale of a 51% stake in Creo Medical Europe and cost management efforts, have strengthened its balance sheet. The company is optimistic about future growth, targeting a 40%-60% increase in Core Technology revenue for FY25, supported by new product launches and strategic partnerships.
More about Creo Medical
Creo Medical Group PLC is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on enhancing surgical capabilities and patient outcomes through its CROMA platform, powered by Kamaptive technology, which integrates multi-modal energy sources for procedures such as resection, dissection, coagulation, and ablation. Creo aims to provide safer, less invasive, and cost-efficient surgical options.
Average Trading Volume: 1,209,025
Technical Sentiment Signal: Sell
Current Market Cap: £41.76M
For a thorough assessment of CREO stock, go to TipRanks’ Stock Analysis page.